Topics:
Thoracic Malignancies • Medical Oncology • NCI-CCC Tumor Board Question • Non-small cell lung cancer • University of Michigan • NCI-CCC Thoracic Tumor Board Question
What is your approach to adjuvant therapy for an R0, ALK+ resected lung adenocarcinoma with N2 disease?
Answer from: Medical Oncologist at Academic Institution
This is a timely question for me as well as the community. For me as I have just had my first patient presenting with ALK-positive 3A cancer PREOPERATIVELY. For the community as there was a recent presentation at ESMO of the ALINA trial. In the ALINA trial, patients with ALK-positive NSCLC were rand...
Sign in or Register to read more